ASTRAZENECA PLCAZN

時価総額

PER

革新的医薬品の最大手。がん、循環器、希少疾患向けのバイオ医薬品や放射性標的治療を展開。2024年6月にFusionを2,195百万ドルで買収。2024年の製品売上は50,938百万ドル、80カ国超で展開。

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Product Sales	20,152	21,049	23,565	25,890	36,541	42,998	43,789	50,938
Alliance Revenue	-	-	-	-	-	-	1,428	2,212
Collaboration Revenue	-	-	819	727	876	1,353	594	923
Total Revenue	22,465	22,090	24,384	26,617	37,417	44,351	45,811	54,073
Cost of sales	4,318	4,936	4,921	5,299	12,437	12,391	8,268	10,207
Gross profit	18,147	17,154	19,463	21,318	24,980	31,960	37,543	43,866
Distribution expense	310	331	339	399	446	536	539	555
Research and development expense	5,757	5,932	6,059	5,991	9,736	9,762	10,935	13,583
Selling, general and administrative expense	10,233	10,031	11,682	11,294	15,234	18,419	19,216	19,977
Other operating income (expense)	1,830	2,527	1,541	1,528	1,492	514	1,340	252
Operating profit	3,677	3,387	2,924	5,162	1,056	3,757	8,193	10,003
Finance income	113	138	172	87	43	95	344	458
Finance expense	1,508	1,419	1,432	1,306	1,300	1,346	1,626	1,742
Share of after tax losses in associates and joint ventures	-55	-113	-116	-27	-64	-5	-12	-28
Profit before tax	2,227	1,993	1,548	3,916	-265	2,501	6,899	8,691
Taxation	-641	-57	321	772	-380	-792	938	1,650
Profit for the period	2,868	2,050	1,227	3,144	115	3,293	5,961	7,041
Remeasurement of the defined benefit pension liability	-242	-46	-364	-168	626	1,118	-406	80
Other comprehensive income, before tax, gains (losses) from investments in equity instruments	-	-171	-28	938	-187	-88	278	139
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss	-9	8	-5	-1	-	2	-6	12
Tax on items that will not be reclassified to profit and loss	-16	-56	-21	81	-105	216	-101	43
Total other comprehensive income that will not be reclassified to profit and loss, net of tax	-235	-153	-376	688	544	816	-33	188
Foreign exchange arising on consolidation	-	-	-	-	-	-1,446	608	-957
Foreign exchange arising on designated liabilities in net investment hedges	-	-	-	-	-	-	-	-122
Fair value movements on cash flow hedges	311	-37	-101	180	-167	-97	266	-129
Fair value movements on cash flow hedges transferred to profit and loss	315	-111	-52	254	-208	-73	145	-177
Fair value movements on derivatives designated in net investment hedges	-	-	-	-	34	-8	44	39
Costs of hedging	-	-	-	-	-	-7	-19	-21
Tax on items that may be reclassified subsequently to profit and loss	33	-51	-38	39	-46	-73	12	-25
Other comprehensive (loss)/income that may be reclassified to profit and loss, net of tax	874	-906	-235	920	-689	-1,694	766	-988
Other comprehensive (expense)/income for the period, net of tax	639	-1,059	-611	1,608	-145	-878	733	-800
Total comprehensive income for the period	3,507	991	616	4,752	-30	2,415	6,694	6,241
Owners of the Parent	3,001	2,155	1,335	3,196	112	3,288	5,955	7,035
Non-controlling interests	-133	-105	-108	-52	3	5	6	6
Owners of the Parent	3,640	1,097	723	4,804	-33	2,413	6,688	6,236
Non-controlling interests	-133	-106	-107	-52	3	2	6	5
Total comprehensive income for the period	3,507	991	616	4,752	-30	2,415	6,694	6,241
Basic earnings (loss) per share	2.37	1.7	1.03	2.44	0.08	2.12	3.84	4.54
Diluted earnings (loss) per share	2.37	1.7	1.03	2.44	0.08	2.11	3.81	4.5